Clinical trials: Adenocarcinoma of the Prostate
Prostate Adenocarcinoma, Prostate Carcinoma
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body.
- Conditions
- Prostate Adenocarcinoma, Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer
- Trial name
- NCT00170157
- Testing
- Bicalutamide, Flutamide, Goserelin Acetate
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Mayo Clinic
Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage I Prostate Cancer AJCC v8
Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer
This phase II trial studies how well olaparib works in treating participants with prostate cancer that has not spread to other parts of the body (localized).
- Conditions
- Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8
- Trial name
- NCT03570476
- Testing
- Olaparib, Radical Prostatectomy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington
Adenocarcinoma of Prostate
Short-term High Precision Radiotherapy for Early Prostate Cancer With Concomitant Boost on the Dominant Lesion
The present research project aims to improve the current treatment for prostate-confined tumor, evaluating the safety and feasibility of a very short hypofractionated radiotherapy schedule administered with one of the best…
- Trial name
- NCT01913717
- Testing
- External beam radiotherapy
- Where
- Italy
- Volunteers
- 65 people
- Sponsor
- European Institute of Oncology
Prostate Cancer
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT01083368
- Testing
- temsirolimus, bevacizumab, polymorphism analysis
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for the treatment of men with prostate cancer who are starting long-term ADT for the first time, termed hormone-naïve prostate cancer.
- Trial name
- STAMPEDE (NCT00268476)
- Testing
- Celecoxib, Docetaxel, Prednisolone
- Where
- 120 sites in Switzerland, United Kingdom
- Volunteers
- 11,992 people
- Sponsor
- Medical Research Council
MSI-H Colorectal Cancer, Melanoma
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors.
- Conditions
- MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma, Mesothelioma
- Trial name
- ACROPOLI (NCT04802876)
- Testing
- Spartalizumab, Tislelizumab
- Where
- Spain
- Volunteers
- 184 people
- Sponsor
- SOLTI Breast Cancer Research Group
Prostate Adenocarcinoma, Localized Prostate Carcinoma
Two-fraction HDR Monotherapy for Localized Prostate Cancer
This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart.
- Trial name
- NCT05665738
- Testing
- High Dose Rate Monotherapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
Prostate Adenocarcinoma
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
This study is designed to evaluate the initial safety and effectiveness of an investigational drug, niraparib, given to patients who have recently received platinum-based chemotherapy for the treatment of prostate cancer.
- Trial name
- NCT04288687
- Testing
- Niraparib Pill
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
This phase II trial investigates how well ZEN-3694, enzalutamide, and pembrolizumab work in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT04471974
- Testing
- BET Bromodomain Inhibitor ZEN-3694, Enzalutamide, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- Rahul Aggarwal
Localized Prostate Carcinoma, Prostate Adenocarcinoma
Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study
This clinical trial studies the effects of a diet and physical activity intervention on blood measures of lipids and insulin resistance in patients with prostate cancer undergoing radiation therapy (RT) and androgen deprivation…
- Trial name
- NCT04870515
- Testing
- Best Practice, Dietary Intervention, Exercise Intervention
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Pain, Prostate Cancer
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00005960
- Testing
- filgrastim, cyclophosphamide, docetaxel
- Where
- 6 sites in United States
- Sponsor
- Amgen
Prostate Cancer, Prostatic Adenocarcinoma
Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
Degarelix is an approved drug that is used to treat prostate cancer by lowering testosterone levels in the body. Degarelix is commonly given with radiation for prostate cancer, but less frequently with surgery since there has…
- Trial name
- NCT01542021
- Testing
- degarelix injection, androgen deprivation therapy
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adenocarcinoma of the Prostate
Single Photon Emission Computed Tomography (SPECT) Lymph Node Mapping
The purpose of this study is to determine if the planning of radiation treatment of prostate cancer patient can be made more precise by comparing currently planning techniques to an imaging technique called SPECT.
- Trial name
- SPECT (NCT00608920)
- Testing
- Single Photon Emission Computed Tomography (SPECT)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Prostate Adenocarcinoma, Incontinence Stress
A Prospective Study to Evaluate the Impact of Maximal Urethral Length Preservation Technique During Robotic Laparoscopic Prostatectomy on the Stretched Flaccid Penile Length and Continence
After robotic prostatectomy, besides erectile function and achievement of oncological control, staying dry is also a very important desire expressed frequently by the patients.
- Conditions
- Prostate Adenocarcinoma, Incontinence Stress, Erectile Dysfunction Following Radical Prostatectomy
- Trial name
- NCT05735223
- Testing
- Maximal urethral length preservation technique of robot assisted radical prostatectomy (RALP).
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Larkin Health System
Adenocarcinoma of Prostate, Adenocarcinoma of the Prostate Stage I
Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial
This is a psychosocial/behavioral study and does not involve administration of any treatment or diagnostic procedures. We will use a randomized trial to test the hypothesis that a decision analysis model that provides…
- Conditions
- Adenocarcinoma of Prostate, Adenocarcinoma of the Prostate Stage I, Adenocarcinoma of the Prostate Stage II, Adenocarcinoma of the Prostate Stage III
- Trial name
- NCT02024685
- Testing
- Personalized Treatment Recommendations, Standard patient-physician counseling interaction
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer, Prostate Adenocarcinoma
Two-Fraction Ultrahypofractionated Radiotherapy With Focal Boost for Intermediate Risk, Localized Prostate Cancer
The goal of this clinical trial is to assess the non-inferiority irradiating low and intermediate risk, localized prostate cancer in two fractions of radiotherapy, compared to five fractions of radiotherapy which is the standard…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Localized Prostate Carcinoma
- Trial name
- TURBO (NCT06518226)
- Testing
- Ultrahypofractionated MRgRT in 2 fractions, Standard of care: MRgRT in 5 fractions
- Where
- Netherlands
- Volunteers
- 160 people
- Sponsor
- UMC Utrecht
Prostate Cancer
Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer
The purpose of this study is to determine the safety and effectiveness of the combination of docetaxel and ZD1839 on destroying prostate cancer before removal of the prostate.
- Trial name
- NCT00242918
- Testing
- docetaxel, ZD1839
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Benaroya Research Institute
Prostate Adenocarcinoma, Localized Prostate Carcinoma
Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP)
This study is a two-arm, multicenter, randomized controlled clinical trial on whether single-port extraperitoneal VIP RARP is non-inferior to multi-port transperitoneal RARP in terms of functional recovery rate and other key…
- Trial name
- NCT06238713
- Testing
- Single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy（VIP） techniques, Multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Shanghai Changzheng Hospital
Prostate Cancer
Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NRR (NCT00225420)
- Testing
- docetaxel, leuprolide acetate, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer
Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as flutamide and buserelin may stop the adrenal glands from producing androgens.
- Trial name
- NCT00054106
- Testing
- buserelin, custirsen sodium, flutamide
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- NCIC Clinical Trials Group